PDP Pediapharm

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES


Pediapharm Inc. ("Pediapharm") (TSX VENTURE:PDP) and Merz Pharma Canada, Ltd.
("Merz") announce they have entered into an agreement regarding the Canadian
rights to CUVPOSA(TM) (glycopyrrolate) oral solution intended for pediatric
chronic severe drooling (sialorrhea) associated with neurologic conditions such
as cerebral palsy. Pediapharm was granted exclusive commercial rights for the
product in Canada.


"Merz is pleased to be expanding patient and physician access to Cuvposa(TM)
(glycopyrrolate) oral solution through this new agreement with Pediapharm," said
Bob Bennett, President and General Manager of Merz Pharma Canada. "We are
dedicated to improving the quality of life for patients suffering from movement
and neurological disorders such as cerebral palsy, and we look forward to
collaborating with Pediapharm in order to achieve this goal."


Cerebral palsy (CP) is a lifelong condition that encompasses a group of
non-progressive, neurological disorders affecting body movement and muscle
coordination.


"Based on our discussions with experts in the field, chronic severe drooling is
a poorly managed condition in up to 30% of children with CP. Because the
treatment options available in Canada are limited, this may lead to various
health issues and a decreased quality of life in that patient population", said
Benoit Hebert, Pediapharm's Vice President of Business Development and
Licensing. "We are delighted to collaborate with Merz in bringing this
opportunity to the Canadian market as this transaction is a good example of what
Pediapharm can accomplish".


CUVPOSA(TM) was approved by the FDA in July 2010 and has been commercially
available in the U.S. since April 2011. It is the only FDA-approved treatment to
reduce chronic severe drooling in pediatric patients (aged 3-16) with neurologic
conditions associated with problem drooling. Sialorrhea is a common problem for
individuals with neurologic conditions, especially children with cerebral palsy.


"CUVPOSA(TM) will be an important addition to our portfolio of innovative
products and further strengthens our commitment to becoming the recognized
leader in the treatment of diseases and conditions affecting children" said
Sylvain Chretien, President and Chief Executive Officer of Pediapharm Inc. "This
transaction reflects our desire to accelerate the growth of the corporation by
offering to Canadian healthcare providers the necessary products to treat
pediatric unmet medical needs."


Pediapharm intends to register the product with Health Canada during 2014 and,
if approved, expects to launch the product in 2015.


About CUVPOSA(TM)

CUVPOSA(TM) is a competitive inhibitor of acetylcholine receptors that are
located on certain peripheral tissues, including salivary glands. CUVPOSA(TM)
indirectly reduces the rate of salivation by preventing stimulation of these
receptors. CUVPOSA(TM) is available under prescription in the United States as a
1mg/5ml clear, cherry flavored oral solution.


Results of a randomized, double-blind, placebo-controlled Phase 3 study of 38
patients showed that 75% of children and adolescents, aged 3-16, treated with
CUVPOSA(TM) experienced an improvement in symptoms of chronic severe drooling at
week 8, versus 11% who received placebo. Dry mouth, vomiting, constipation,
flushing and nasal congestion were the most commonly reported adverse reactions.


About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. 


About Merz North America

Merz North America is a specialty healthcare company that develops and
commercializes innovative treatment solutions in medical and aesthetic
dermatology, and neurology in the U.S. and Canada. Our ambition is to become a
recognized leader in the treatment of movement disorders, and in aesthetics and
dermatology. Our future is promising, and we are committed to advancing new
therapeutic options and improving patients' lives. For more than 100 years, the
development of our products has been based on Merz's commitment to providing
innovative medical approaches that earn trust of patients, physicians and
partners worldwide. Globally, the companies of Merz Pharma Group are focused on
medications for treating neurological and psychiatric illnesses, and they have
assumed a leading role in the field of Alzheimer's disease research. Founded in
1908, Merz Pharma Group is a privately owned company headquartered in Frankfurt,
Germany.


FORWARD LOOKING STATEMENTS FOR PEDIAPHARM

This news release contains forward-looking statements and other statements that
are not historical. Such forward-looking statements are subject to known and
unknown risks, uncertainties and assumptions that could cause actual results to
vary materially from target results and the results or events predicted in these
forward-looking statements. As a result, investors are cautioned not to place
undue reliance on these forward-looking statements.


The forward-looking statements contained in this news release are made as of the
date of this release. Except as required by applicable law, the Corporation
disclaims any intention and assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. Forward-looking information reflects the current
expectations or belief of the Corporation based on information currently
available and such information is subject to a number of assumptions, risks and
uncertainties described in details at pp. 35 to 41 of the Management Information
Circular of Chelsea Acquisition Corporation dated November 12, 2013 available on
SEDAR at www.sedar.com and other risks associated with being a specialty
pharmaceutical company.


For more information about Pediapharm or its products, please visit
www.pedia-pharm.com.


For more information about Merz or the Company's products, please visit
www.merzusa.com 


CUVPOSA(TM) is a trademark of Merz Pharmaceuticals, LLC.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sylvain Chretien
President and Chief Executive Officer
Pediapharm Inc.
+1-514-762-2626 ext. 201
sylvain.chretien@pedia-pharm.com


Roland Boivin
Chief Financial Officer
Pediapharm Inc.
+1-514-762-2626 ext. 202
roland.boivin@pedia-pharm.com


Merz North America
Mariana Smith
Corporate Communications
Office (336) 217-2636
Mariana.Smith@merz.com

Pediapharm Inc. (TSXV:PDP)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Pediapharm Inc. (TSXV:PDP)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024